Literature DB >> 18479439

Extensively drug-resistant tuberculosis: current challenges and threats.

Amita Jain1, Rajesh Mondal.   

Abstract

Extensively drug-resistant tuberculosis (XDR-TB) is defined as tuberculosis caused by a Mycobacterium tuberculosis strain that is resistant to at least rifampicin and isoniazid among the first-line antitubercular drugs (multidrug-resistant tuberculosis; MDR-TB) in addition to resistance to any fluroquinolones and at least one of three injectable second-line drugs, namely amikacin, kanamycin and/or capreomycin. Recent studies have described XDR-TB strains from all continents. Worldwide prevalence of XDR-TB is estimated to be c. 6.6% in all the studied countries among multidrug-resistant M. tuberculosis strains. The emergence of XDR-TB strains is a reflection of poor tuberculosis management, and controlling its emergence constitutes an urgent global health reality and a challenge to tuberculosis control activities in all parts of the world, especially in developing countries and those lacking resources and as well as in countries with increasing prevalence of HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479439     DOI: 10.1111/j.1574-695X.2008.00400.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  37 in total

Review 1.  The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors.

Authors:  L Hedstrom; G Liechti; J B Goldberg; D R Gollapalli
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.

Authors:  Silke Feuerriegel; Helen S Cox; Nana Zarkua; Hamraev A Karimovich; Kai Braker; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 3.  Differentiation of Crohn's disease from intestinal tuberculosis in India in 2010.

Authors:  Anna Benjamin Pulimood; Deepak Narayan Amarapurkar; Ujjala Ghoshal; Mathew Phillip; Cannanore Ganesh Pai; Duvvur Nageshwar Reddy; Birender Nagi; Balakrishna Siddhartha Ramakrishna
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

4.  Lantibiotics as prospective antimycobacterial agents.

Authors:  John Donaghy
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

5.  rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.

Authors:  Patrick Beckert; Doris Hillemann; Thomas A Kohl; Jörn Kalinowski; Elvira Richter; Stefan Niemann; Silke Feuerriegel
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 6.  Epidemiological models of Mycobacterium tuberculosis complex infections.

Authors:  Cagri Ozcaglar; Amina Shabbeer; Scott L Vandenberg; Bülent Yener; Kristin P Bennett
Journal:  Math Biosci       Date:  2012-03-01       Impact factor: 2.144

Review 7.  Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis.

Authors:  Hugh Salamon; Ken D Yamaguchi; Daniela M Cirillo; Paolo Miotto; Marco Schito; James Posey; Angela M Starks; Stefan Niemann; David Alland; Debra Hanna; Enrique Aviles; Mark D Perkins; David L Dolinger
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

8.  Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.

Authors:  Sylvia R Luckner; Carl A Machutta; Peter J Tonge; Caroline Kisker
Journal:  Structure       Date:  2009-07-15       Impact factor: 5.006

9.  Mycobacterium tuberculosis phosphoribosylpyrophosphate synthetase: biochemical features of a crucial enzyme for mycobacterial cell wall biosynthesis.

Authors:  Anna P Lucarelli; Silvia Buroni; Maria R Pasca; Menico Rizzi; Andrea Cavagnino; Giovanna Valentini; Giovanna Riccardi; Laurent R Chiarelli
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

10.  Phenylalanine-rich peptides potently bind ESAT6, a virulence determinant of Mycobacterium tuberculosis, and concurrently affect the pathogen's growth.

Authors:  Krishan Kumar; Megha Tharad; Swetha Ganapathy; Geeta Ram; Azeet Narayan; Jameel Ahmad Khan; Rana Pratap; Anamika Ghosh; Sachin Kumar Samuchiwal; Sushil Kumar; Kuhulika Bhalla; Deepti Gupta; Krishnamurthy Natarajan; Yogendra Singh; Anand Ranganathan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.